Sunday 18 October 2026
Export ATTO’s income statement to Excel — free account
Attovia Therapeutics, Inc.
ATTO
Insiders bought in the last twelve months.
13.73
1.05
−7.10%
Follow ATTO
| Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|
P/S ratio |
— | — | 0.00 |
P/FCF ratio |
— | — | 0.00 |
P/Operating CF |
— | — | 0.00 |
P/B ratio |
— | — | 0.00 |
Price to Tangible BV |
— | — | 0.00 |
EV/Sales |
— | — | 0.00 |
EV/EBITDA |
— | — | 0.00 |
EV/Operating CF |
— | — | 0.00 |
EV/FCF |
— | — | 0.00 |
Quick Ratio |
— | 13.83 | 9.13 |
Current Ratio |
— | 14.20 | 9.39 |
Net Debt/EBITDA |
0.00 | 0.00 | 5.28 |
Debt/Assets |
— | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | — | 4,210.22% |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 734.89% |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% |
Graham Net Nets |
— | — | (1.67) |
Graham Number |
— | — | 0.00 |
Free Cash Flow Yield |
— | — | 0.00% |
Revenue per Share |
0.00 | — | 0.11 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
0.00 | 0.00 | 27.17 |
Shareholders Equity per Share |
0.00 | 0.00 | (34.33) |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
0.00 | 0.00 | (34.33) |
EV/EBIT |
— | — | 0.00 |
Capex to Sales |
— | — | 0.00 |
Price to Operating Income |
— | — | 0.00 |
| Other line items | |||
Working Capital |
— | 145.29 | 105.79 |
Net Current Asset Value |
— | (117.03) | (155.41) |
Columns are period end dates · fundamentals updated 29 Sep 2026